Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

11/4/24 11:46:39 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IRWD alert in real time by email

SC 13G/A 1 UnitedStates_13G__IronwoodPh.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Ironwood Pharmaceuticals Inc (Title of Class of Securities) Common Stock (CUSIP Number) 46333X108 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 46333X108 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 333,123 (7) Sole dispositive power 21,550,638 (8) Shared dispositive power 487,459 (9) Aggregate amount beneficially owned by each reporting person 22,038,097 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 13.79% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Ironwood Pharmaceuticals Inc Item 1(b) Address of issuer's principal executive offices: 100 Summer Street Suite 2300 Boston, MA 02110 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 46333X108 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 22,038,097 (b) Percent of class: 13.79% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 22,038,097 (b) Percent of class: 13.79% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 333,123 (iii) Sole power to dispose or to direct the disposition of: 21,550,638 (iv) Shared power to dispose or to direct the disposition of: 487,459 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acqui

Get the next $IRWD alert in real time by email

Recent Analyst Ratings for

$IRWD

Date	Price Target	Rating	Analyst
9/9/2024	$5.00	Market Perform	Leerink Partners
8/8/2024	$12.00 → $4.00	Overweight → Equal Weight	CapitalOne
1/17/2024	$21.00	Buy	Craig Hallum
12/14/2023	$20.00	Overweight	Wells Fargo
11/9/2023	$21.00	Buy	Jefferies
9/28/2023	$22.00	Mkt Outperform	JMP Securities
9/2/2022	$15.00	Overweight	CapitalOne
4/22/2022	$16.00	Overweight	Piper Sandler

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for $IRWD

$IRWD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Duane Jon R bought $60,204 worth of shares (6,920 units at $8.70), increasing direct ownership by 6% to 121,028 units (SEC Form 4)

Emany Sravan Kumar bought $100,216 worth of shares (10,684 units at $9.38), increasing direct ownership by 4% to 301,733 units (SEC Form 4)

SEC Form 4: Emany Sravan Kumar bought $300,119 worth of shares (36,072 units at $8.32), increasing direct ownership by 24% to 188,730 units

$IRWD Press Releases

Fastest customizable press release news feed in the world

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

$IRWD SEC Filings

Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$IRWD Leadership Updates

Live Leadership Updates

Memo Therapeutics AG appoints Paul Carter as Chairperson

Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer

$IRWD Financials

Live finance-specific insights

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call

$IRWD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Denner Alexander J was granted 3,282 shares, increasing direct ownership by 2% to 152,104 units (SEC Form 4)

Chief Legal Officer John Minardo sold $42,316 worth of shares (9,910 units at $4.27), decreasing direct ownership by 3% to 284,661 units (SEC Form 4)

Principal Accounting Officer Silver Ronald sold $13,267 worth of shares (3,107 units at $4.27), decreasing direct ownership by 2% to 158,370 units (SEC Form 4)

$IRWD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners initiated coverage on Ironwood Pharma with a new price target

Ironwood Pharma downgraded by CapitalOne with a new price target

Craig Hallum initiated coverage on Ironwood Pharma with a new price target

$IRWD Large Ownership Changes

This live feed shows all institutional transactions in real time.